Effects of indomethacin and dexamethasone on mechanical scratching-induced cutaneous barrier disruption in mice.
Effects of indomethacin and dexamethasone on recovery of cutaneous barrier disruption induced by mechanical scratching were examined. Cutaneous barrier was disrupted by scratching using a stainless-steel wire brush (mechanical scratching) and compared to cutaneous application of acetone/ether (1:1) mixture (AE) and tape-stripping. Increase of transepidermal water loss (TEWL), as an indicator of a broken skin barrier, and recovery period for mechanical scratching were higher and longer than those for AE treatment and tape-stripping and we also confirmed the severity of skin damage in a histological study. Topical application of moisturizers showed a temporal effect, rapidly decreased TEWL on mechanical scratching- or AE treatment-induced cutaneous barrier disruption, and gradually increased base levels from 4 to 12 h after treatment. Topical application of indomethacin or dexamethasone prolonged the recovery period for the cutaneous barrier, and concomitant use further worsened the status of the barrier. Additionally, we examined the effects of prostaglandins (PGs) and inflammatory cytokine on mechanical scratching-induced cutaneous barrier disruption pretreated with indomethacin and dexamethasone. As a results, PGD2 and interleukin (IL)-1beta significantly accelerated the recovery of cutaneous barrier disruption by mechanical scratching but such was not the case with PGE2, IL-1alpha, and tumor necrosis factor-alpha treatment. These results suggest that indomethacin and dexamethasone prolonged the recovery period caused by inhibition of PGD2 and IL-1beta. Mechanical scratching-induced cutaneous barrier disruption may be a useful method for evaluating means of recovery from skin damage.
Honma
Yusuke
Y
Department of Pharmacology Laboratory, Medical Research Laboratories, Taisho Pharmaceutical Co. Ltd, Saitama, Japan. y.honma@po.rd.taisho.co.jp
Arai
Iwao
I
Sakurai
Takanobu
T
Futaki
Nobuko
N
Hashimoto
Yuki
Y
Sugimoto
Masanori
M
Nakanishi
Yutaka
Y
Nakaike
Shiro
S
D000096:Acetone / Q000494:pharmacology; D000818:Animals; D003907:Dexamethasone / Q000494:pharmacology*; D004817:Epidermis / Q000737:chemistry / Q000187:drug effects / Q000502:physiology; D004986:Ether / Q000494:pharmacology; D005990:Glycerol / Q000494:pharmacology; D007150:Immunohistochemistry; D007213:Indomethacin / Q000494:pharmacology*; D007375:Interleukin-1 / Q000032:analysis / Q000494:pharmacology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D010577:Petrolatum / Q000494:pharmacology; D015230:Prostaglandin D2 / Q000494:pharmacology; D017472:Receptors, Interleukin-1 / Q000032:analysis; D053573:Receptors, Interleukin-1 Type I; D012867:Skin / Q000187:drug effects* / Q000293:injuries / Q000503:physiopathology; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D014867:Water / Q000378:metabolism; D014870:Water Loss, Insensible / Q000187:drug effects*
D007375:Interleukin-1; D017472:Receptors, Interleukin-1; D053573:Receptors, Interleukin-1 Type I; D014409:Tumor Necrosis Factor-alpha; D014867:Water; D004986:Ether; D000096:Acetone; D003907:Dexamethasone; D010577:Petrolatum; D005990:Glycerol; D015230:Prostaglandin D2; D007213:Indomethacin